Call for expressions of interest for inclusion on a list of experts to be used by the EUDA Executive Director to extend the Scientific Committee for the risk assessment of new psychoactive substances

This call is addressed to scientists who wish to be considered for inclusion on a list of experts to be used by the Executive Director to extend the Scientific Committee for the purposes of ensuring a balanced assessment of the risks posed by new psychoactive substances in accordance with Article 10 and Article 31 of the EUDA Regulation (1).

The official text of the announcement/notice of the call for expressions of interest was published in the Official Journal (2023/S 215-678001).

About EUDA

On 2 July 2024, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) will become the European Union Drugs Agency (EUDA) in accordance with Regulation (EU) 2023/1322 of the European Parliament and of the Council of 27 June 2023 on the European Union Drugs Agency (EUDA) and repealing Regulation (EC) No 1920/2006 (1).

The European Union Drug Agency (EUDA), based in Lisbon, Portugal, was established to provide the European Union and its Member States with

  1. factual, objective, reliable and comparable information, early warning and risk assessment at Union level concerning drugs, drug use, drug use disorders and addictions, prevention, treatment, care, risk and harm reduction, rehabilitation, social reintegration, recovery, drug markets and supply, including illicit production and trafficking, and other relevant drug related issues and their consequences;
  2. and recommend appropriate and concrete evidence-based actions on how to address the challenges set out in point (a) in an efficient and timely manner.

For additional information on EUDA, please see New legislation grants Europe stronger powers to tackle current and future drug problems.

About the extended Scientific Committee

Role and Composition

The risk assessment of new psychoactive substances is carried out by the Scientific Committee extended as required by additional experts, in accordance with Article 10 of the EUDA Regulation. During a risk assessment, the Scientific Committee is required to assess the following areas:

(a) Available information on the chemical and physical properties of the new psychoactive substance and the methods and the precursors used for its manufacture or extraction.

(b) Available information on the pharmacological and toxicological properties of the new psychoactive substance.

(c) An analysis of the health risks associated with the new psychoactive substance, in particular with respect to its acute and chronic toxicity, abuse liability, dependence-producing potential, and physical, mental and behavioural effects.

(d) An analysis of the social risks associated with the new psychoactive substance – in particular its impact on social functioning, public order and criminal activities, and the involvement of criminal groups in the manufacture, distribution and distribution methods, and trafficking of the new psychoactive substance.

(e) Available information on the extent and patterns of use of the new psychoactive substance, its availability and potential for diffusion within the Union.

(f) Available information on the commercial and industrial use of the new psychoactive substance, the extent of such use, as well as its use for scientific research and development purposes.

(g) Other relevant information, where available.

Therefore, the expertise required for the list includes experts from the following scientific fields and areas: chemistry; pharmacology; toxicology; (neuro)biological and behavioural sciences; medicine; public health; risk management; botany; psychology; sociology; prevention; treatment; regulation; crime; and, economics.

The selected experts will be included, in a personal capacity, on a list to be approved by the EUDA Management Board for a four-year period. The experts from the approved list shall be independent and shall act in the public interest. They shall neither seek nor take instructions from any government or from any other body. The EUDA Management Board may decide to extend the validity of the approved list of experts for further four years.

Pursuant to the rules applicable for the definition of the list of experts to be used to extend the EUDA Scientific Committee for the purposes of the assessment of the risks posed by new psychoactive substances, these experts must be nationals of a Member State of the European Union (EU) or of a Country which has concluded an agreement with the latter for the purpose of the participation in the work of the EUDA. This requirement is a condition of eligibility for the selection and the inclusion on the above referred list. If this condition is not met, this will determine the exclusion of the concerned person from the selection process and/or from the approved list of experts, as from the moment when this condition is not met.

Meetings

Risk assessment meetings are held on an ad hoc basis in accordance with Article 10 of the EUDA Regulation  at the EUDA premises in Lisbon. The vehicular working language of the risk assessment procedure and risk assessment meetings is English.

Each expert designated by the Executive Director to extend the Scientific Committee for the purpose of a risk assessment will be entitled to receive an allowance for each day of attendance to the meeting held for this assessment. Furthermore, they will be entitled to the refunding of the travel, accommodation and subsistence expenses exposed for this attendance. The conditions and terms of the above-referred entitlements will be the ones applied for the appointed members of the Scientific Committee, in accordance with the rules in force at EUDA for this purpose.

Declarations of independence and interest

Each expert designated by the Executive Director to extend the Scientific Committee for the purpose of a risk assessment shall sign a declaration of independence in relation to the performance of his/her duties in and for this body, and shall fill in and sign a written declaration of interest covering current and past interests up to five years before the date of the declaration. These declarations will be made available for public scrutiny on the EUDA website, with due respect to EU rules on protection of personal data.

Instructions for applying

1. Please read carefully the complete information on this call:

2. Complete the application form

  • Please ensure that you also include a short letter of introduction, stating why you are interested in being included on the list of experts.
  • Please note that you will need to register with EU Login in order to access the application form on EUSurvey.

If you have a question about this call, please email to: LOE@emcdda.europa.eu

Closing date

The closing date for submission of expressions of interest is 17.01.2024 at 23h59, Lisbon time (date and hour of submission to EUSurvey). The EMCDDA/EUDA reserves the right to disregard any expressions of interest submitted after that date.

 

 

Top